Moa Technology Raises £22.2M to Advance Resistance-Breaking Herbicides

Modern agriculture is facing an uncomfortable imbalance.

Weeds continue to evolve resistance, but the crop-protection industry has spent decades working with many of the same biological targets. Applying more of an existing product may offer temporary control. It does not solve the underlying resistance problem.

Oxford agricultural biotechnology company Moa Technology has raised £22.2 million in Series C funding to advance a new generation of herbicides designed to work through previously unused biological mechanisms. Oxford Science Enterprises and Supernova Invest co-led the financing.

New investors included Agri Investment Fund, GrainInnovate, Infinity Investment Partners and Magdalen College Oxford. Existing backers Oxford Science Enterprises, Lansdowne Partners, Parkwalk and Oxford University Innovation also participated.

Spun out of the University of Oxford in 2017 by Professor Liam Dolan and Clément Champion, Moa is led by CEO Dr. Virginia Corless. The company is not attempting to improve one established herbicide. It has rebuilt the early discovery process around finding entirely different ways to disrupt weed biology.

The industry needs new biological targets, not another variation

Herbicides are commonly classified by their mode of action—the biological process they interrupt inside a plant.

When products repeatedly attack the same process, weed populations can gradually develop resistance. The agricultural consequence is larger than a failed treatment: resistant weeds compete with crops for water, nutrients, sunlight and space, reducing the productivity of farmland.

Moa’s GALAXY platform screens miniaturized whole plants against large chemical libraries. Imaging and biological analysis are then used to identify compounds producing plant responses that differ from known commercial herbicides.

The company says its platforms have now screened more than 900,000 compounds and discovered over 80 promising novel mode-of-action areas. Its earlier blinded testing reported approximately 96% accuracy when classifying compounds with known modes of action, although these figures are based on company research.

Three programs are moving closer to the field

The new capital will move Moa’s three most advanced programs significantly closer to commercialization while supporting earlier-stage candidates in its pipeline.

Those programs have progressed beyond laboratory and glasshouse validation into international field trials. Moa says its leading candidates have continued to control difficult weeds across successive growing seasons.

This stage is where agricultural biotechnology becomes particularly demanding. A compound must perform across different climates, crops, soil conditions and weed populations. It must also satisfy extensive safety, environmental and regulatory requirements before farmers can use it commercially.

The Series C will be supplemented by upfront and milestone payments from Moa’s current and future industry partners. During the past two years, the company has formed research collaborations with Nufarm, Gowan, Certis Belchim and Corteva Agriscience.

These partnerships give Moa access to crop-protection development and commercialization capabilities while allowing established agricultural companies to reach potential new chemistry without rebuilding their own discovery engines.

Moa Amplifiers could make existing products work harder

One of the more unusual programs funded by the round does not begin with a standalone herbicide.

In 2025, Moa identified a new category called Moa Amplifiers. These compounds are not intended to kill weeds independently. Instead, they may increase the effectiveness of another herbicide, potentially allowing farmers to achieve control using a lower amount or concentration of the main product.

That approach could extend the useful life of existing crop-protection tools while new modes of action move through longer commercial development cycles.

Its value will depend on whether the effect remains consistent under field conditions and whether the combined products deliver a practical economic and environmental advantage for growers.

Discovery speed is no longer the only test

Moa has demonstrated that its platform can generate a large number of novel biological leads. The Series C begins a different test.

Investors and commercial partners will now look for candidates that can survive years of optimization, safety assessment, regulatory review and field validation. Farmers will ultimately care about an even simpler outcome: whether the product controls resistant weeds reliably without making crop production less economical.

Moa’s £22.2 million round is therefore not just funding another screening campaign. It is financing the difficult transition from discovering an unfamiliar biological mechanism to placing a dependable product in a farmer’s hands.

Source : Moa Technology Official Announcement